Avidity Biosciences (RNA)
(Delayed Data from NSDQ)
$44.48 USD
-1.17 (-2.56%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $44.49 +0.01 (0.02%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Price, Consensus and EPS Surprise
RNA 44.48 -1.17(-2.56%)
Will RNA be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for RNA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for RNA
Company News for Aug 13, 2024
Avidity Biosciences, Inc. (RNA) Reports Q2 Loss, Misses Revenue Estimates
RNA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q2 Loss, Misses Revenue Estimates
Avidity (RNA) Up 33% on Rare Muscle Disease Study Results
Coherus BioSciences (CHRS) Reports Q1 Loss, Misses Revenue Estimates
Other News for RNA
Cantor Fitzgerald Reaffirms Their Buy Rating on Avidity Biosciences (RNA)
Unveiling 7 Analyst Insights On Avidity Biosciences
RTW Biotech half-year net asset value rises amid "challenging markets"
Avidity Biosciences Joins Patient and Advocacy Communities in Raising Awareness During National Muscular Dystrophy Awareness Month
Dyne stock tumbles 31% amid drug updates, management changes